FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)															
1. Name and Address of Reporting Person * Lin Patrick				2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) C/O PROCESSA PHARMACEUTICALS, INC., 7380 COCA COLA DRIVE, SUITE 106				3. Date of Earliest Transaction (Month/Day/Year) 08/05/2021						X Officer (give title below) Other (specify below) Chief Business - Strategy Off							
(Street) HANOVER, MD 21076					4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)					Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		(Instr. 8				of (D) Benefici		iciall ted T	ally Owned Following I Transaction(s)		Form: Direct (D)	7. Nature of Indirect Beneficial Ownership		
						Code	V Amount (A) or (D) Pri		Price					or Indirect (I) (Instr. 4)	(Instr. 4)		
Common	n Stock		08/05/2021			A		7,601	A	(1)	418,8	390			D		
Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	(Month/Day/	3A. Deemed Execution Date	e.g., puts, 4. Trar Cod	calls, was a saction e e ar. 8)	arrants, o	red, D pptions 6. D and (Mo	isposed , conver ate Exer Expirati nth/Day	of, or Ben etible secur reisable on Date /Year)	eficial rities) 7. T Am Und Sect (Ins 4)	lly Owi	l i i i i i i i i i i i i i i i i i i i	8. Price of	9. Number Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	of 10. Owners Form o Derivat Securit Direct (or Indii	f Beneficive Owne (Instruction)	
							Rela	tionship	os								
Reporting Owner Name / Address				Director 10% Owner			Officer				Othe	r					
Lin Patrick C/O PROCESSA PHARMACEUTICALS, INC 7380 COCA COLA DRIVE, SUITE 106 HANOVER, MD 21076				·.			Chief Business - Strategy										
Signa	tures																
/s/ Patrio	ck Lin by N	Michael B. I	Kirwan, as Attorn	ev-in-Fa	ıct	0	8/09/2	2021									

Date

Explanation of Responses:

**Signature of Reporting Person

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Vesting of time-based restricted shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.